Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Read more about Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Read more about Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Read more about Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Read more about Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Read more about Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Solid organ transplant rejection associated with immune-checkpoint inhibitors. Read more about Solid organ transplant rejection associated with immune-checkpoint inhibitors.
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Read more about Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Read more about Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use? Read more about Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Read more about Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
